Background and Purpose

The Prescription Drug User Fee Act (PDUFA) was enacted by Congress in 1992, authorizing the FDA to levy fees on companies that manufacture certain human drugs and biologics. The primary purpose was to secure funding to accelerate the new‑drug approval process. Fee revenues have been used to expand FDA personnel and systems, contributing to reduced approval waiting times.

Why an Amendment Is Needed Now

The pace of therapeutic development has surged, and the complexity of biosimilars and gene therapies has increased, straining review capacity under existing budgets. Consequently, the FDA seeks to modernize its infrastructure and establish an evaluation framework that reflects the latest scientific advances through an expanded fee structure. This is expected to enhance regulatory efficiency and lower market entry barriers.

Implications for the Industry

Manufacturers will face higher fee burdens, but the trade‑off is faster approvals that allow earlier product launch and quicker revenue recovery. Large pharmaceutical companies are likely to accelerate the market entry of their existing pipelines to secure competitive advantage, while smaller firms may pursue strategic partnerships to mitigate cost pressures. This dynamic will prompt a re‑configuration of collaboration models between the FDA and industry.

Future Scenarios and Impact

If fee expansions succeed, the FDA can hire additional staff to accelerate the assessment of complex clinical data and minimize cost losses associated with approval delays. Conversely, excessive fees could suppress innovative investment by small companies, risking a slowdown in new‑drug development across the biotech sector. Therefore, tiered fee application based on company size emerges as a critical consideration in policy design.